Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 03, 2018

SELL
$6.93 - $14.63 $0 - $0
0 Closed
0 $0
Q1 2018

Apr 20, 2018

SELL
$8.71 - $14.82 $87 - $148
-10 Closed
0 $0
Q4 2017

Feb 22, 2018

SELL
$7.8 - $12.94 $7,722 - $12,810
-990 Reduced 99.0%
10 $0
Q3 2017

Oct 27, 2017

BUY
$10.9 - $12.73 $10,900 - $12,730
1,000
1,000 $12,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $934M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Cable Hill Partners, LLC Portfolio

Follow Cable Hill Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cable Hill Partners, LLC with notifications on news.